Secukinumab efficacy in the treatment of pediatricpsoriasis in China: a case series

Abstract

Introduction: There is a lack of data on the use of biologic therapy inrefractory pediatric psoriasis in China. This study presents pediatric psoriasis cases treated with Secukinumab in our center. Case presentation: In this retrospective case series,we collected the data of moderate to severe psoriasis patients under 18 years old treated with secukinumab in our hospital from 2019 to 2020. The demographic data, previous treatments, efficacy and side effects were recorded and analyzed. Discussion: These five patients had a median age of 10 years (8-17) with a median history of plaque psoriasis of 2 years.At Week 4, 3 out of 5 cases have achieved PASI 75, and at Week 16, 100% of the patients have achieved PASI 100.No adverse events occurred. Conclusion: It is safe and effective to treat recalcitrant pediatric psoriasis with secukinumab. Larger series are needed to confirm our observation.